Denileukin Diftitox and Lorlatinib

• Generic Name: denileukin diftitox
• Dosage Forms: n.a.
• Other Brand Names: Ontak

Treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) in patients whose malignant cells express the CD25 component of the IL-2 receptor (designated an orphan drug by FDA for this use).

Safety and efficacy in patients with CTCL whose malignant cells do not express the CD25 component of the IL-2 receptor not established but currently being studied.

• Generic Name: lorlatinib
• Dosage Forms: n.a.
• Other Brand Names: Lorbrena

Lorlatinib is used to treat a certain type of non-small cell lung cancer that has spread to other parts of the body.

Lorlatinib is used only if your cancer has a specific genetic marker (an abnormal "ALK" gene). Your doctor will test you for this gene.

Lorlatinib is given after other cancer treatments did not work or have stopped working.

Lorlatinib was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to lorlatinib, but further studies are needed.

Lorlatinib may also be used for purposes not listed in this medication guide.